Results 231 to 240 of about 179,970 (275)
Some of the next articles are maybe not open access.
Postmenopausal osteoporosis and atheroma
Joint Bone Spine, 2006Epidemiological studies have established a significant association between two major health problems, osteoporosis and atheroma, which is independent from age, gender, and other cardiovascular risk factors. Bone loss and the development of calcific deposits within vessel walls occur concomitantly.
Gérald, Rajzbaum, Yvonnick, Bézie
openaire +2 more sources
ESTROGENS AND POSTMENOPAUSAL OSTEOPOROSIS
Clinical Obstetrics and Gynecology, 1976A model for the development of osteoporosis is presented and the tre atment of the condition with estrogens is discussed. It appears that an age-related reduction in circulating estrogens accompanies menopausal bone loss. However this loss is more directly attributable to the lack of parathyroid hormone (PTH) while estrogens play a role in the bony ...
openaire +2 more sources
Calcitriol for Postmenopausal Osteoporosis
Annals of Internal Medicine, 1990Excerpt To the Editor:Gallagher and Riggs (1) recently criticized the report by Ott and Chesnut (2) on calcitriol treatment in postmenopausal osteoporosis.
openaire +2 more sources
Treatment of Postmenopausal Osteoporosis
New England Journal of Medicine, 1998Osteoporosis affects an estimated 75 million people in Europe, the United States, and Japan.1 It is a preventable and treatable condition, yet many people with osteoporosis remain unrecognized and untreated. The purpose of this review is to consider the evidence that treatments for postmenopausal osteoporosis are effective and safe.
openaire +2 more sources
Osteoporosis in postmenopausal women
The Journal of Prosthetic Dentistry, 1984Eleven postmenopausal complete denture patients participated in a study to evaluate some possible predictors of osteoporosis. Most participants in the study reported a low caloric intake and consumed considerably less than the recommended daily allowances of sodium, cholesterol, calcium, fluoride, magnesium, zinc, and folic acid.
R P, Renner, L J, Boucher, H W, Kaufman
openaire +2 more sources
Postmenopausal osteoporosis and alendronate
Maturitas, 2004Osteoporosis is a systemic metabolic disorder associated with a decreased bone mass and resistance. Bisphosphonates suppress bone resorption and bone turnover by a mechanism that depends on their structure. They are characterized by low gastrointestinal absorption. In postmenopausal women, alendronate (ALN) reduces bone resorption markers and increases
openaire +2 more sources
Management of Postmenopausal Osteoporosis
Annual Review of Medicine, 2015A hallmark of menopause, which follows the decline in the ovarian production of estrogen, is the aggressive and persistent loss of bone mineral and structural elements leading to loss of bone strength and increased fracture risk. This review focuses on newer methods of diagnosing osteoporosis and assessing fracture risk, as well as on novel management
Panagiota, Andreopoulou +1 more
openaire +2 more sources
Bisphosphonates for postmenopausal osteoporosis
Bone, 2011Bisphosphonates are effective in reducing bone turnover, increasing BMD and reducing fracture risk in postmenopausal women with osteoporosis. The licensed bisphosphonates exhibit some differences in potency and speed of onset and offset of action.
Richard, Eastell +3 more
openaire +2 more sources
Treatment of postmenopausal osteoporosis
The Lancet, 2002The aim of treatment of postmenopausal osteoporosis is to reduce the frequency of vertebral and non-vertebral fractures (especially at the hip), which are responsible for morbidity associated with the disease. Results of large placebo controlled trials have shown that alendronate, raloxifene, risedronate, the 1-34 fragment of parathyroid hormone, and ...
openaire +2 more sources